Kiora Pharmaceuticals Inc
KPRX2.050USD
-0.070-3.30%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
7.04MMarket Cap
LossP/E TTM
More Details of Kiora Pharmaceuticals Inc Company
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Kiora Pharmaceuticals Inc Info
Ticker SymbolKPRX
Company nameKiora Pharmaceuticals Inc
IPO dateFeb 13, 2015
CEOStrem (Brian M)
Number of employees12
Security typeOrdinary Share
Fiscal year-endFeb 13
Address169 Saxony Rd.
CityENCINITAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92024
Phone18582249600
Websitehttps://kiorapharma.com/
Ticker SymbolKPRX
IPO dateFeb 13, 2015
CEOStrem (Brian M)
Company Executives of Kiora Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Melissa Tosca, CPA
Ms. Melissa Tosca, CPA
Chief Financial Officer
Chief Financial Officer
21.37K
+57.16%
Ms. Erin Parsons
Ms. Erin Parsons
Independent Director
Independent Director
5.26K
--
Mr. Praveen Tyle, Ph.D.
Mr. Praveen Tyle, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.01K
+0.04%
Mr. Aron Shapiro
Mr. Aron Shapiro
Director
Director
3.00K
--
Ms. Lisa Walters-Hoffert
Ms. Lisa Walters-Hoffert
Independent Director
Independent Director
1.25K
--
Dr. Eric J. Daniels, M.D.
Dr. Eric J. Daniels, M.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Carmine Stengone
Mr. Carmine Stengone
Independent Director
Independent Director
--
--
Dr. David A. Hollander, M.D.
Dr. David A. Hollander, M.D.
Independent Director
Independent Director
--
--
Dr. Brian M. Strem, Ph.D.
Dr. Brian M. Strem, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Melissa Tosca, CPA
Ms. Melissa Tosca, CPA
Chief Financial Officer
Chief Financial Officer
21.37K
+57.16%
Ms. Erin Parsons
Ms. Erin Parsons
Independent Director
Independent Director
5.26K
--
Mr. Praveen Tyle, Ph.D.
Mr. Praveen Tyle, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.01K
+0.04%
Mr. Aron Shapiro
Mr. Aron Shapiro
Director
Director
3.00K
--
Ms. Lisa Walters-Hoffert
Ms. Lisa Walters-Hoffert
Independent Director
Independent Director
1.25K
--
Dr. Eric J. Daniels, M.D.
Dr. Eric J. Daniels, M.D.
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Adar1 Capital Management LLC
4.57%
Nantahala Capital Management, LLC
4.25%
Stonepine Capital Management, LLC
3.82%
Lincoln Park Capital, LLC
2.77%
Strem (Brian M.)
1.25%
Other
83.33%
Shareholders
Shareholders
Proportion
Adar1 Capital Management LLC
4.57%
Nantahala Capital Management, LLC
4.25%
Stonepine Capital Management, LLC
3.82%
Lincoln Park Capital, LLC
2.77%
Strem (Brian M.)
1.25%
Other
83.33%
Shareholder Types
Shareholders
Proportion
Hedge Fund
10.69%
Investment Advisor
4.44%
Investment Advisor/Hedge Fund
4.34%
Individual Investor
2.98%
Research Firm
0.12%
Other
77.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
40
724.05K
21.09%
-1.02M
2025Q2
49
1.51M
49.54%
-309.06K
2025Q1
49
1.37M
46.43%
-406.88K
2024Q4
52
1.35M
44.94%
-452.57K
2024Q3
53
1.75M
62.87%
+166.58K
2024Q2
49
1.48M
54.35%
-132.58K
2024Q1
52
1.49M
72.21%
+1.04M
2023Q4
45
83.35K
12.56%
-79.14K
2023Q3
54
109.42K
21.03%
-9.93K
2023Q2
56
146.95K
33.06%
+106.31K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Adar1 Capital Management LLC
167.11K
4.87%
-27.55K
-14.15%
Jun 30, 2025
Nantahala Capital Management, LLC
43.17K
1.26%
-167.94K
-79.55%
Aug 08, 2025
Stonepine Capital Management, LLC
178.00K
5.18%
-22.65K
-11.29%
Jun 30, 2025
Lincoln Park Capital, LLC
101.94K
2.97%
+87.48K
+605.01%
Apr 16, 2025
Strem (Brian M.)
46.10K
1.34%
+16.02K
+53.24%
Apr 16, 2025
Daniels (Eric Joseph)
26.38K
0.77%
+7.80K
+41.99%
Apr 16, 2025
Tosca (Melissa)
21.37K
0.62%
+7.77K
+57.16%
Apr 16, 2025
The Vanguard Group, Inc.
2.08K
0.06%
+200.00
+10.67%
Aug 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 07, 2024
Merger
9→1
Jun 07, 2024
Merger
9→1
Jun 07, 2024
Merger
9→1
Jun 07, 2024
Merger
9→1
Sep 26, 2022
Merger
40→1
Sep 26, 2022
Merger
40→1
Date
Type
Ratio
Jun 07, 2024
Merger
9→1
Jun 07, 2024
Merger
9→1
Jun 07, 2024
Merger
9→1
Jun 07, 2024
Merger
9→1
Sep 26, 2022
Merger
40→1
Sep 26, 2022
Merger
40→1
Sep 26, 2022
Merger
40→1
Sep 26, 2022
Merger
40→1
FAQs
Who are the top five shareholders of Kiora Pharmaceuticals Inc?
The top five shareholders of Kiora Pharmaceuticals Inc are:
Adar1 Capital Management LLC holds 167.11K shares, accounting for 4.87% of the total shares.
Nantahala Capital Management, LLC holds 43.17K shares, accounting for 1.26% of the total shares.
Stonepine Capital Management, LLC holds 178.00K shares, accounting for 5.18% of the total shares.
Lincoln Park Capital, LLC holds 101.94K shares, accounting for 2.97% of the total shares.
Strem (Brian M.) holds 46.10K shares, accounting for 1.34% of the total shares.
Adar1 Capital Management LLC holds 167.11K shares, accounting for 4.87% of the total shares.
Nantahala Capital Management, LLC holds 43.17K shares, accounting for 1.26% of the total shares.
Stonepine Capital Management, LLC holds 178.00K shares, accounting for 5.18% of the total shares.
Lincoln Park Capital, LLC holds 101.94K shares, accounting for 2.97% of the total shares.
Strem (Brian M.) holds 46.10K shares, accounting for 1.34% of the total shares.
What are the top three shareholder types of Kiora Pharmaceuticals Inc?
The top three shareholder types of Kiora Pharmaceuticals Inc are:
Adar1 Capital Management LLC
Nantahala Capital Management, LLC
Stonepine Capital Management, LLC
Adar1 Capital Management LLC
Nantahala Capital Management, LLC
Stonepine Capital Management, LLC
How many institutions hold shares of Kiora Pharmaceuticals Inc (KPRX)?
As of 2025Q3, 40 institutions hold shares of Kiora Pharmaceuticals Inc, with a combined market value of approximately 724.05K, accounting for 21.09% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -28.45%.
What is the biggest source of revenue for Kiora Pharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for Kiora Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
